Printer Friendly

BIOSOURCE INTERNATIONAL ANNOUNCES DEVELOPMENT AGREEMENT WITH BENDER MEDSYSTEMS

 CAMARILLO, Calif., Aug. 3 /PRNewswire/ -- BioSource International Inc. (NASDAQ: BIOI) today announced that it has entered into a joint development agreement with Bender MedSystems (Vienna, Austria) a wholly owned subsidiary of the Boehringer-Inglehiem Group.
 The agreement calls for BioSource and Bender MedSystems to jointly develop four new ELISA assays to measure murine (mouse) immunological molecules. BioSource is a leading supplier of immunoassay ELISA kits, which are used in laboratory research to detect and measure levels of specific target molecules in samples. Since mice are frequently used as model animals in the study of inflammatory disorders, cancer and AIDS, these assays are expected to have large utility in biomedical research programs.
 BioSource will obtain and produce the basic materials and develop protocols for the test kits, and transfer them to Bender MedSystems for manufacturing in Europe. Bender MedSystems will have exclusive European marketing rights to the four products produced under the initial agreement, which will be manufactured and sold in North America exclusively by BioSource.
 "The joint development agreement allows us to efficiently expand one of our core product areas while developing an important working relationship with one of the world's leading pharmaceutical concerns," said James Chamberlain, president and CEO of BioSource. "This marks an important stage in BioSource's growth as a supplier of assays, reagents and other test products for laboratory applications."
 Chamberlain estimated that the worldwide market for murine cytokine assays is approximately $2 million annually. The company expects to realize revenues of $0.25 to $0.5 million annually from the joint effort, based on fees paid by Bender MedSystems for development and delivery of the ELISA kit materials and revenues from assay sales by BioSource.
 "BioSource, Bender MedSystems and its parent company, the Boehringer-Inglehiem Group, will be discussing additional product development and marketing agreements," said Chamberlain. "These products, such as human assays for both research and diagnostic applications, would appropriately leverage our expertise in designing high-quality assays and test reagents with the international reach of one of the world's largest pharmaceutical concerns."
 NOTE: BioSource International Inc. is a Camarillo-based supplier of immunological reagents and test kits used in biomedical research. The company offers more than 600 products, including recombinant proteins, monoclonal antibodies and ELISA assay kits to a variety of antigens. Incorporated in 1989, the company was listed on Nasdaq in 1993, after completing the acquisition of Tago, Inc. Combined FY 1992 revenues of the merged company were $4 million. First quarter 1993 (Jan. 1-March 31) revenues were $1.26 million, and the company reported net income of $0.16 million.
 -0- 8/3/93
 /CONTACT: James Chamberlain, president, or Anna Anderson, chief financial officer, of BioSource International, 805-987-0086; or Matthew Schmidt of FS Communications, 415-691-1488, for BioSource International/
 (BIOI)


CO: BioSource International Inc.; Bender MedSystems;
 Boehringer-Ingleheim Group ST: California IN: MTC SU:


CB-TM -- SJ006 -- 8835 08/03/93 11:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 3, 1993
Words:475
Previous Article:DUFF & PHELPS RATES LIFE PARTNERS GROUP, INC., MASSACHUSETTS GENERAL LIFE INSURANCE COMPANY AND PHILADELPHIA LIFE INSURANCE COMPANY
Next Article:ARCADIAN TO EXPAND NITROGEN CAPACITY
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters